NcXHF

KREM AND GOPAL
(NCT00796731). Paper presented at: 2011 ASCO Annual Meeting; June
2011; Chicago, IL.
75. Palanca-Wessels MC, Salles GA, Czuczman MS, et al. Final results of a
phase I study of the anti-CD79b antibody-drug conjugate DCDS4501A
in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).
Presented at: The 55th Annual Meeting of the American Society of Hematology;
December 2013; New Orleans, Louisiana.
76. Gopal AK, Tarantolo SR, Bellam N, et al. Phase 1b study of TRU-016, an
anti-CD37 SMIP protein, in combination with rituximab and bendamustine
in relapsed indolent lymphoma. Paper presented at: 54th Annual
ASH Meeting and Exposition; December 2012; Atlanta, GA.
77. Davila ML, Bouhassira DC, Park JH, et al. Chimeric antigen receptors
for the adoptive T cell therapy of hematologic malignancies. Int J Hematol.
2014;99:361-371.
78. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage
cells and regression of lymphoma in a patient treated with autologous T
cells genetically engineered to recognize CD19. Blood. 2010;116:4099-
4102.
79. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptormodifıed
T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:
725-733.
80. Chung EY, Psathas JN, Yu D, et al. CD19 is a major B cell receptorindependent
activator of MYC-driven B-lymphomagenesis. J Clin Invest.
2012;122:2257-2266.
81. de Vos S, Flowers CR, Wang D, et al. The BCL-2 inhibitor ABT-199
(GDC-0199) in combination with bendamustine and rituximab in patients
with relapsed or refractory non-Hodgkin’s lymphoma. Presented
at: The 56th Annual Meeting of the American Society of Hematology;
December 2014; San Francisco, California.
82. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by
pidilizumab in combination with rituximab in patients with relapsed
follicular lymphoma: a single group, open-label, phase 2 trial. Lancet
Oncol. 2014;15:69-77.
83. Lesokhin AM, Ansell SM, Armand P, et al. Preliminary results of a phase
I study of nivolumab (BMS-936558) in patients with relapsed or refractory
lymphoid malignancies. Presented at: The 56th Annual Meeting of
the American Society of Hematology; December 2014; San Francisco,
California.
e374
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook